Simvastatin inhibits IFN-γ-induced CD40 gene expression by suppressing STAT-1α

Journal of Leukocyte Biology

Volumn 82, Issue 2, 2007, Pages 436-447

  Sun, Jung Lee ^a   Qin, Hongwei ^a   Benveniste, Etty N ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

JAK STAT pathway; Macrophage; Statins

Indexed keywords

CD40 ANTIGEN; GAMMA INTERFERON; GUANINE NUCLEOTIDE BINDING PROTEIN; HISTONE H3; HISTONE H4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MEVALONIC ACID; RHO FACTOR; RNA POLYMERASE; SIMVASTATIN; STAT1 PROTEIN;

ACETYLATION; ANIMAL CELL; ARTICLE; AUTOCRINE EFFECT; CONTROLLED STUDY; DRUG ACTIVITY; GENE EXPRESSION; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, CD40; CELL LINE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERFERON TYPE II; MACROPHAGES, PERITONEAL; MICE; SIMVASTATIN; STAT1 TRANSCRIPTION FACTOR;

CLOSTRIDIUM DIFFICILE;

EID: 34547769908     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.1206739     Document Type: Article

References (64)

1. Boehm, U., Klamp, T., Groot, M., Howard, J. C. (1997) Cellular responses to interferon-γ. Annu. Rev. Immunol. 15, 749-795.
2. Shuai, K., Liu, B. (2003) Regulation of JAK-STAT signaling in the immune system. Nat. Rev. Immunol. 3, 900-911.
3. Decker, T., Kovarik, P. (2000) Serine phosphorylation of STATs. Oncogene 19, 2628-2637.
4. Schönbeck, U., Libby, P. (2001) The CD40/CD154 receptor/ligand dyad. Cell. Mol. Life Sci. 58, 4-43.
5. Town, T., Tan, J., Mullan, M. (2001) CD40 signaling and Alzheimer's disease pathogenesis. Neurochem. Int. 39, 371-380.
6. Gerritse, K., Laman, J. D., Noelle, R. J., Aruffo, A., Ledbetter, J. A., Boersma, W. J., Claassen, E. (1996) CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. USA 93, 2499-2504.
7. Benveniste, E. N., Nguyen, V. T., Wesemann, D. R. (2004) Molecular regulation of CD40 gene expression in macrophages and microglia. Brain Behav. Immun. 18, 7-12.
8. Tan, J., Town, T., Crawford, F., Mori, T., DelleDonne, A., Crescentini, R., Obregon, D., Flavell, R. A., Mullan, M. J. (2002) Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat. Neurosci. 5, 1288-1293.
9. Samoilova, E. B., Horton, J. L., Zhang, H., Chen, Y. (1997) CD40L blockade prevents autoimmune encephalomyelitis and hampers TH1 but not TH2 pathway of T cell differentiation. J. Mol. Med. 75, 603-608.
10. Mach, F., Schonbeck, U., Sukhova, G. K., Atkinson, E., Libby, P. (1998) Reduction of atherosclerosis in mice by inhibition of CD40 signaling. Nature 394, 200-203.
11. Becher, B., Durell, B. G., Miga, A. V., Hickey, W. F., Noelle, R. J. (2001) The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system. J. Exp. Med. 193, 967-974.
12. Nguyen, V. T., Benveniste, E. N. (2000) Involvement of STAT-1 and ets family members in interferon-γ induction of CD40 transcription in microglia/ macrophages. J. Biol. Chem. 275, 23674-23684.
13. Wesemann, D. R., Dong, Y., O'Keefe, G. M., Nguyen, V. T., Benveniste, E. N. (2002) Suppressor of cytokine signaling 1 inhibits cytokine induction of CD40 expression in macrophages. J. Immunol. 169, 2354-2360.
14. Nguyen, V. T., Benveniste, E. N. (2002) Critical role of tumor necrosis factor-α and NF-κ B in interferon-γ-induced CD40 expression in microglia/ macrophages. J. Biol. Chem. 277, 13796-13803.
15. Goldstein, J. L., Brown, M. S. (1990) Regulation of the mevalonate pathway. Nature 343, 425-430.
16. Topol, E. J. (2004) Intensive statin therapy - a sea change in cardiovascular prevention. N. Engl. J. Med. 350, 1562-1564.
17. Weber, M. S., Youssef, S., Dunn, S. E., Prod'homme, T., Neuhaus, O., Stuve, O., Greenwood, J., Steinman, L., Zamvil, S. S. (2006) Statins in the treatment of central nervous system autoimmune disease. J. Neuroimmunol. 178, 140-148.
18. Jain, M. K., Ridker, P. M. (2005) Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat. Rev. Drug Discov. 4, 977-987.
19. Greenwood, J., Steinman, L., Zamvil, S. S. (2006) Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol. 6, 358-370.
20. Cordle, A., Landreth, G. (2005) 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate β-amyloid-induced microglial inflammatory responses. J. Neurosci. 25, 299-307.
21. Etienne-Manneville, S., Hall, A. (2002) Rho GTPases in cell biology. Nature 420, 629-635.
22. Zhang, F. L., Casey, P. J. (1996) Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65, 241-269.
23. Menge, T., Hartung, H. P., Stuve, O. (2005) Statins - a cure-all for the brain? Nat. Rev. Neurosci. 6, 325-331.
24. Kwak, B., Mulhaupt, F., Myit, S., Mach, F. (2000) Statins as a newly recognized type of immunomodulator. Nat. Med. 6, 1399-1402.
25. Neuhaus, O., Strasser-Fuchs, S., Fazekas, F., Kieseier, B. C., Niederwieser, G., Hartung, H. P., Archelos, J. J. (2002) Statins as immunomodulators: comparison with interferon-β 1b in MS. Neurology 59, 990-997.
26. Youssef, S., Stuve, O., Patarroyo, J. C., Ruiz, P. J., Radosevich, J. L., Hur, E. M., Bravo, M., Mitchell, D. J., Sobel, R. A., Steinman, L., Zamvil, S. S. (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420, 78-84.
27. Townsend, K. P., Shytle, D. R., Bai, Y., San, N., Zeng, J., Freeman, M., Mori, T., Fernandez, F., Morgan, D., Sanberg, P., Tan, J. (2004) Lovastatin modulation of microglial activation via suppression of functional CD40 expression. J. Neurosci. Res. 78, 167-176.
28. Nakamichi, K., Saiki, M., Kitani, H., Kuboyama, Y., Morimoto, K., Takayama-Ito, M., Kurane, I. (2006) Suppressive effect of simvastatin on interferon-β-induced expression of CC chemokine ligand 5 in microglia. Neurosci. Lett. 407, 205-210.
29. Bi, X., Baudry, M., Liu, J., Yao, Y., Fu, L., Brucher, F., Lynch, G. (2004) Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia. J. Biol. Chem. 279, 48238-48245.
30. Wong, B., Lumma, W. C., Smith, A. M., Sisko, J. T., Wright, S. D., Cai, T. Q. (2001) Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J. Leukoc. Biol. 69, 959-962.
31. Lindberg, C., Crisby, M., Winblad, B., Schultzberg, M. (2005) Effects of statins on microglia. J. Neurosci. Res. 82, 10-19.
32. Oh, J. W., Van Wagoner, N. J., Rose-John, S., Benveniste, E. N. (1998) Role of IL-6 and the soluble IL-6 receptor in inhibition of VCAM-1 gene expression. J. Immunol. 161, 4992-4999.
33. Wesemann, D. R., Benveniste, E. N. (2003) STAT-1 α and IFN-γ as modulators of TNF-α signaling in macrophages: regulation and functional implications of the TNF receptor 1:STAT-1 α complex. J. Immunol. 171, 5313-5319.
34. Nguyen, V. T., Walker, W. S., Benveniste, E. N. (1998) Post-transcriptional inhibition of CD40 gene expression in microglia by transforming growth factor-β. Eur. J. Immunol. 28, 2537-2548.
35. Ma, Z., Shah, R. C., Chang, M. J., Benveniste, E. N. (2004) Coordination of cell signaling, chromatin remodeling, histone modifications, and regulator recruitment in human matrix metalloproteinase 9 gene transcription. Mol. Cell. Biol. 24, 5496-5509.
36. Finder, J. D., Litz, J. L., Blaskovich, M. A., McGuire, T. F., Qian, Y., Hamilton, A. D., Davies, P., Sebti, S. M. (1997) Inhibition of protein geranylgeranylation causes a superinduction of nitric-oxide synthase-2 by interleukin-1β in vascular smooth muscle cells. J. Biol. Chem. 272, 13484-13488.
37. Dunn, S. E., Youssef, S., Goldstein, M. J., Prod'homme, T., Weber, M. S., Zamvil, S. S., Steinman, L. (2006) Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J. Exp. Med. 203, 401-412.
38. Just, I., Wilm, M., Selzer, J., Rex, G., von Eichel-Streiber, C., Mann, M., Aktories, K. (1995) The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins. J. Biol. Chem. 270, 13932-13936.
39. Qin, H., Wilson, C. A., Lee, S. J., Zhao, X., Benveniste, E. N. (2005) LPS induces CD40 gene expression through the activation of NF-κB and STAT-1α in macrophages and microglia. Blood 106, 3114-3122.
40. Qin, H., Wilson, C. A., Lee, S. J., Benveniste, E. N. (2006) IFN-β-induced SOCS-1 negatively regulates CD40 gene expression in macrophages and microglia. FASEB J. 20, 985-987.
41. Struhl, K. (1998) Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 12, 599-606.
42. Huang, K. C., Chen, C. W., Chen, J. C., Lin, W. W. (2003) Statins induce suppressor of cytokine signaling-3 in macrophages. FEBS Lett. 555, 385-389.
43. Sadeghi, M. M., Tiglio, A., Sadigh, K., O'Donnell, L., Collinge, M., Pardi, R., Bender, J. R. (2001) Inhibition of interferon-γ-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation 71, 1262-1268.
44. Chung, H. K., Lee, I. K., Kang, H., Suh, J. M., Kim, H., Park, K. C., Kim, D. W., Kim, Y. K., Ro, H. K., Shong, M. (2002) Statin inhibits interferon-γ-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp. Mol. Med. 34, 451-461.
45. Platanias, L. C. (2005) Mechanisms of type-I- and type-II-interferon- mediated signaling. Nat. Rev. Immunol. 5, 375-386.
46. Neufeld, E. B., Cooney, A. M., Pitha, J., Dawidowicz, E. A., Dwyer, N. K., Pentchev, P. G., Blanchette-Mackie, E. J. (1996) Intracellular trafficking of cholesterol monitored with a cyclodextrin. J. Biol. Chem. 271, 21604-21613.
47. Togo, T., Akiyama, H., Kondo, H., Ikeda, K., Kato, M., Iseki, E., Kosaka, K. (2000) Expression of CD40 in the brain of Alzheimer's disease and other neurological diseases. Brain Res. 885, 117-121.
48. Tan, J., Town, T., Mullan, M. (2002) CD40-CD40L interaction in Alzheimer's disease. Curr. Opin. Pharmacol. 2, 445-451.
49. Nath, N., Giri, S., Prasad, R., Singh, A. K., Singh, I. (2004) Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J. Immunol. 172, 1273-1286.
50. Aktas, O., Waiczies, S., Smorodchenko, A., Dorr, J., Seeger, B., Prozorovski, T., Sallach, S., Endres, M., Brocke, S., Nitsch, R., Zipp, F. (2003) Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med. 197, 725-733.
51. Mulhaupt, F., Matter, C. M., Kwak, B. R., Pelli, G., Veillard, N. R., Burger, F., Graber, P., Luscher, T. F., Mach, F. (2003) Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc. Res. 59, 755-766.
52. Wagner, A. H., Gebauer, M., Guldenzoph, B., Hecker, M. (2002) 3-Hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 22, 1784-1789.
53. Yilmaz, A., Reiss, C., Weng, A., Cicha, I., Stumpf, C., Steinkasserer, A., Daniel, W. G., Garlichs, C. D. (2006) Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J. Leukoc. Biol. 79, 529-538.
54. Lee, Y. J., Benveniste, E. N. (1996) Stat1 α expression is involved in IFN-γ induction of the class II transactivator and class II MHC genes. J. Immunol. 157, 1559-1568.
55. Bai, L., Merchant, J. L. (2003) Transcription factor ZBP-89 is required for STAT1 constitutive expression. Nucleic Acids Res. 31, 7264-7270.
56. Rasmussen, L. M., Hansen, P. R., Nabipour, M. T., Olesen, P., Kristiansen, M. T., Ledet, T. (2001) Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem. J. 360, 363-370.
57. Pahan, K., Sheikh, F. G., Namboodiri, A. M., Singh, I. (1997) Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest. 100, 2671-2679.
58. Madonna, R., Di Napoli, P., Massaro, M., Grilli, A., Felaco, M., De Caterina, A., Tang, D., De Caterina, R., Geng, Y. J. (2005) Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts. J. Biol. Chem. 280, 13503-13511.
59. Huang, K. C., Chen, C. W., Chen, J. C., Lin, W. W. (2003) HMG-CoA reductase inhibitors inhibit inducible nitric oxide synthase gene expression in macrophages. J. Biomed. Sci. 10, 396-405.
60. Matsumoto, M., Einhaus, D., Gold, E. S., Aderem, A. (2004) Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors. J. Immunol. 172, 7377-7384.
61. Coward, W. R., Marei, A., Yang, A., Vasa-Nicotera, M. M., Chow, S. C. (2006) Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes. J. Immunol. 176, 5284-5292.
62. Vollmer, T., Key, L., Durkalski, V., Tyor, W., Corboy, J., Markovic-Plese, S., Preiningerova, J., Rizzo, M., Singh, I. (2004) Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363, 1607-1608.
63. McCarey, D. W., McInnes, I. B., Madhok, R., Hampson, R., Scherbakov, O., Ford, I., Capell, H. A., Sattar, N. (2004) Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomized placebo-controlled trial. Lancet 363, 2015-2021.
64. Rockwood, K., Kirkland, S., Hogan, D. B., MacKnight, C., Merry, H., Verreault, R., Wolfson, C., McDowell, I. (2002) Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 59, 223-227.